抗体药物偶联物 (ADC) 现在是许多癌症的一种经过验证的治疗药物，它将高度特异性的靶向性与高效有效负载的效力相结合。本综述总结了 ADC 在脑肿瘤中的应用经验，并探讨了它们在这些肿瘤中的未来应用途径。本综述将涵盖已在原发性脑肿瘤中进行测试的所有关键类别 ADC，包括对迄今为止主要试验的评论。这些试验的功效及其局限性将放在脑肿瘤药物开发的整体背景下。重要的是，这篇综述将总结这些试验的关键经验和见解，有助于为有效、适当地开发这些药物用于原发性脑肿瘤患者的基本原理奠定基础。脑肿瘤中的 ADC 开发分为两个主要阶段日期。之前试验的主要经验为继续开发这些治疗原发性脑肿瘤的药物提供了强有力的理由。然而，这些肿瘤独特的生物学特性需要专门定制的开发策略，以最大限度地提高其最佳发展。

Antibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the experience with ADCs in brain tumors and examines future paths for their use in these tumors.This review will cover all the key classes of ADCs which have been tested in primary brain tumors, including commentary on the major trials to date. The efficacy of these trials, as well as their limitations, will put in context of the overall landscape of drug development in brain tumors. Importantly, this review will summarize key learnings and insights from these trials that help provide the basis for rationale ways in which these drugs can be effectively and appropriate developed for patients with primary brain tumors.ADC development in brain tumors has occurred in two major phases to date. Key learnings from previous trials provide a strong rationale for the continued development of these drugs for primary brain tumors. However, the unique biology of these tumors requires development strategies specifically tailored to maximize their optimal development.